IN BRIEF: Syncona leads GBP22.5 million financing in Mosaic

Syncona Ltd - healthcare company focused on a portfolio of global leaders in life science - Leads ...

Alliance News 4 April, 2023 | 6:29PM
Email Form Facebook Twitter LinkedIn RSS

Syncona Ltd - healthcare company focused on a portfolio of global leaders in life science - Leads GBP22.5 million Series A financing in Mosaic Therapeutics, a Cambridge England-based oncology therapeutics company. Commits GBP16.5 million alongside investment from Cambridge Innovation Capital. Reports holding value in Mosaic is GBP7.3 million following the investment of the first tranche of the Series A commitment and, once all current commitments are invested, will have a 52.8% stake in the business. Mosaic becomes Syncona's 13th company in its current portfolio.

Also announces portfolio company Freeline Therapeutics Holdings PLC results for 2022. Freeline posts narrowed annual pretax loss of USD88.6 million compared to USD140.1 million and loss per share of USD 1.50 against USD3.93. Says Freeline has prioritised the development of its FLT201 therapy in Gaucher Disease, pausing development of the FLT190 programme in Fabry disease. Adds Freeline announced 30% reduction in headcount to around 65.

Current stock price: 149.15 pence

12-month change: down 10%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Syncona Ord 112.20 GBX -2.26 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures